[Sponsored] Is your biotech ready for 2023? MacDougall Advisors has insight
Listen now
Description
Is it all bad news in the bear market? Not necessarily.
After a tumultuous couple of years, many biotechs are looking for signs of improvement in 2023. After all, the biotech sector felt the market pain acutely, particularly over the last 18 months: 2022 marked the longest period of net negative performance for biotech stocks, with the SPDR S&P Biotech ETF XBI extending net losses over a 70-week period.
But things are looking up: the XBI was 7% up in January of this year, and investor sentiment seems to be improving.
Biotechs can look forward to some upward momentum if they take the right strategic steps now. In this podcast, Sara Michelmore and Karen Sharma from MacDougall Advisors share what biotechs can do to position themselves for this market swing.
See omnystudio.com/listener for privacy information.
More Episodes
Published 07/14/23
In this episode of "The Top Line," we talk with Dr Reanne Moore, an associate professor of psychiatry at the University of California San Diego, about the state of digital phenotyping. We also cover the vaccine patent lawsuits, the smallest insulin pump, and the rest of the week's headlines.
To...
Published 07/14/23
For sponsors, value lies in equipping sites with the technology that makes securely capturing pre-screening, recruitment, and enrollment data easier.
In this interview, Alicia Asgari, the Senior Manager of Solutions Consulting at OneStudyTeam, discusses the need for appropriate technology...
Published 07/10/23
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
